{
    "info": {
        "nct_id": "NCT04506554",
        "official_title": "A Phase II Trial of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer",
        "inclusion_criteria": "* Male or female patients ≥18 years\n* Primary urothelial or predominantly urothelial carcinoma of the bladder confirmed from pathology report. Patients with some component of variant histology mixed with predominant urothelial carcinoma will be allowed. Upper tract urothelial carcinoma patients are not allowed.\n* Urothelial carcinoma of the prostatic urethra in men is allowed\n* Histologic evidence of muscularis propria invasion.\n* AJCC23 clinical stage T2-T3 N0M0.\n* No radiographic evidence of lymph node positive disease as per RECIST 1.1 (≥15 mm short axis diameter). Lymph node positive disease is defined as clinical lymphadenopathy on staging CT or MRI greater than 1.4 cm in the short axis. If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible.\n* No metastatic disease (M0).\n* ECOG performance status 0, or 1.\n* Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 6 months of study entry.\n* Negative pregnancy test in women of child bearing potential within 24 hours of study registration. If the pregnancy test is positive, the patient must not receive protocol treatment and must not be enrolled in the study.\n* Normal organ and bone marrow function (Leukocytes ≥ 3,000/mcL, Absolute neutrophil count ≥ 1,500/mcL, Platelets ≥ 100,000/mcL, Total bilirubin ≤ institutional upper limit of normal (ULN) unless patient has known Gilbert's disease, in which case an elevated bilirubin is allowed, AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN, Creatinine Clearance ≥ 50 mL/min calculated using the Cockroft-Gault formula or measured with 24 hour urine collection)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any component of small cell histology.\n* Prior systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible. Patients who received immunotherapy for non-muscle invasive bladder cancer will be excluded\n* Has a known additional malignancy that has had progression or has required active treatments in the last three years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with surgery is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; PSA undetectable for 1 year while off androgen deprivation therapy. Patients on active surveillance for low grade prostate cancer are allowed to participate.\n* Patients who have received experimental agents within 4 weeks of study entry.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined by current oral or intravenous antibiotic therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy.\n* Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.\n* Patients with hydronephrosis that has not been addressed with a documented assessment (i.e. normal GFR, no intervention necessary) or an intervention such as placement of a stent or nephrostomy tube.\n* Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease. Use of steroids as pre-medication for contrast allergy prior to CT scans is permitted. It is acceptable to use steroids as pre-medication for AMVAC.\n* History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n* Prior treatment with CD137 agonists, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents.\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrolment.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Negative pregnancy test in women of child bearing potential within 24 hours of study registration. If the pregnancy test is positive, the patient must not receive protocol treatment and must not be enrolled in the study.",
                "criterions": [
                    {
                        "exact_snippets": "Negative pregnancy test in women of child bearing potential within 24 hours of study registration",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Negative pregnancy test in women of child bearing potential within 24 hours of study registration",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours before study registration"
                            }
                        }
                    },
                    {
                        "exact_snippets": "women of child bearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "women of child bearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "reproductive status",
                            "expected_value": "child bearing potential"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "women of child bearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "women of child bearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "reproductive status",
                                    "expected_value": "child bearing potential"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Negative pregnancy test in women of child bearing potential within 24 hours of study registration",
                                "criterion": "pregnancy test result",
                                "requirement": {
                                    "requirement_type": "result",
                                    "expected_value": "negative"
                                }
                            },
                            {
                                "exact_snippets": "Negative pregnancy test in women of child bearing potential within 24 hours of study registration",
                                "criterion": "pregnancy test result",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 24,
                                        "unit": "hours before study registration"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Histologic evidence of muscularis propria invasion.",
                "criterions": [
                    {
                        "exact_snippets": "Histologic evidence of muscularis propria invasion",
                        "criterion": "muscularis propria invasion",
                        "requirement": {
                            "requirement_type": "histologic evidence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Histologic evidence of muscularis propria invasion",
                        "criterion": "muscularis propria invasion",
                        "requirement": {
                            "requirement_type": "histologic evidence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No metastatic disease (M0).",
                "criterions": [
                    {
                        "exact_snippets": "No metastatic disease (M0)",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No metastatic disease (M0)",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Urothelial carcinoma of the prostatic urethra in men is allowed",
                "criterions": [
                    {
                        "exact_snippets": "Urothelial carcinoma of the prostatic urethra in men is allowed",
                        "criterion": "urothelial carcinoma of the prostatic urethra in men",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Urothelial carcinoma of the prostatic urethra in men is allowed",
                        "criterion": "urothelial carcinoma of the prostatic urethra in men",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* AJCC23 clinical stage T2-T3 N0M0.",
                "criterions": [
                    {
                        "exact_snippets": "AJCC23 clinical stage T2-T3 N0M0",
                        "criterion": "AJCC23 clinical stage",
                        "requirement": {
                            "requirement_type": "T category",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "AJCC23 clinical stage T2-T3 N0M0",
                        "criterion": "AJCC23 clinical stage",
                        "requirement": {
                            "requirement_type": "N category",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "AJCC23 clinical stage T2-T3 N0M0",
                        "criterion": "AJCC23 clinical stage",
                        "requirement": {
                            "requirement_type": "M category",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": ""
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "AJCC23 clinical stage T2-T3 N0M0",
                        "criterion": "AJCC23 clinical stage",
                        "requirement": {
                            "requirement_type": "T category",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "AJCC23 clinical stage T2-T3 N0M0",
                        "criterion": "AJCC23 clinical stage",
                        "requirement": {
                            "requirement_type": "N category",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "AJCC23 clinical stage T2-T3 N0M0",
                        "criterion": "AJCC23 clinical stage",
                        "requirement": {
                            "requirement_type": "M category",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": ""
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant women are excluded from this study",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Pregnant women are excluded from this study",
                    "criterion": "pregnancy status",
                    "requirement": {
                        "requirement_type": "pregnancy",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Known HIV-positive patients on combination antiretroviral therapy are ineligible",
                        "criterion": "HIV-positive status with combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known HIV-positive patients on combination antiretroviral therapy are ineligible",
                        "criterion": "HIV-positive status with combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "combination antiretroviral therapy"
                        }
                    },
                    {
                        "exact_snippets": "Known HIV-positive patients on combination antiretroviral therapy are ineligible",
                        "criterion": "HIV-positive status with combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known HIV-positive patients on combination antiretroviral therapy are ineligible",
                        "criterion": "HIV-positive status with combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known HIV-positive patients on combination antiretroviral therapy are ineligible",
                        "criterion": "HIV-positive status with combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "combination antiretroviral therapy"
                        }
                    },
                    {
                        "exact_snippets": "Known HIV-positive patients on combination antiretroviral therapy are ineligible",
                        "criterion": "HIV-positive status with combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined by current oral or intravenous antibiotic therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined by current oral or intravenous antibiotic therapy)",
                        "criterion": "intercurrent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "ongoing or active infection (defined by current oral or intravenous antibiotic therapy)",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "ongoing or active"
                        }
                    },
                    {
                        "exact_snippets": "symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "cardiac arrhythmia",
                        "criterion": "cardiac arrhythmia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                        "criterion": "psychiatric illness or social situations limiting compliance",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined by current oral or intravenous antibiotic therapy)",
                        "criterion": "intercurrent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "ongoing or active infection (defined by current oral or intravenous antibiotic therapy)",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "ongoing or active"
                        }
                    },
                    {
                        "exact_snippets": "symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "cardiac arrhythmia",
                        "criterion": "cardiac arrhythmia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                        "criterion": "psychiatric illness or social situations limiting compliance",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible. Patients who received immunotherapy for non-muscle invasive bladder cancer will be excluded",
                "criterions": [
                    {
                        "exact_snippets": "Prior systemic chemotherapy or radiation therapy for urothelial carcinoma ... within 1 year of study entry are ineligible",
                        "criterion": "systemic chemotherapy or radiation therapy for urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior systemic chemotherapy or radiation therapy for urothelial carcinoma ... within 1 year of study entry are ineligible",
                        "criterion": "systemic chemotherapy or radiation therapy for urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "prior_treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible",
                        "criterion": "cytotoxic chemotherapy for another malignancy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible",
                        "criterion": "cytotoxic chemotherapy for another malignancy",
                        "requirement": {
                            "requirement_type": "prior_treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients who received immunotherapy for non-muscle invasive bladder cancer will be excluded",
                        "criterion": "immunotherapy for non-muscle invasive bladder cancer",
                        "requirement": {
                            "requirement_type": "prior_treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prior systemic chemotherapy or radiation therapy for urothelial carcinoma ... within 1 year of study entry are ineligible",
                                "criterion": "systemic chemotherapy or radiation therapy for urothelial carcinoma",
                                "requirement": {
                                    "requirement_type": "prior_treatment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Prior systemic chemotherapy or radiation therapy for urothelial carcinoma ... within 1 year of study entry are ineligible",
                                "criterion": "systemic chemotherapy or radiation therapy for urothelial carcinoma",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible",
                                "criterion": "cytotoxic chemotherapy for another malignancy",
                                "requirement": {
                                    "requirement_type": "prior_treatment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible",
                                "criterion": "cytotoxic chemotherapy for another malignancy",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Patients who received immunotherapy for non-muscle invasive bladder cancer will be excluded",
                        "criterion": "immunotherapy for non-muscle invasive bladder cancer",
                        "requirement": {
                            "requirement_type": "prior_treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.",
                "criterions": [
                    {
                        "exact_snippets": "History of autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myasthenia gravis",
                        "criterion": "myasthenia gravis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myositis",
                        "criterion": "myositis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "autoimmune hepatitis",
                        "criterion": "autoimmune hepatitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "systemic lupus erythematosus",
                        "criterion": "systemic lupus erythematosus",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "rheumatoid arthritis",
                        "criterion": "rheumatoid arthritis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "inflammatory bowel disease",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "vascular thrombosis associated with antiphospholipid syndrome",
                        "criterion": "vascular thrombosis associated with antiphospholipid syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Wegener's granulomatosis",
                        "criterion": "Wegener's granulomatosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Sjögren's syndrome",
                        "criterion": "Sjögren's syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Guillain-Barré syndrome",
                        "criterion": "Guillain-Barré syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "multiple sclerosis",
                        "criterion": "multiple sclerosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "vasculitis",
                        "criterion": "vasculitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "glomerulonephritis",
                        "criterion": "glomerulonephritis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myasthenia gravis",
                        "criterion": "myasthenia gravis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myositis",
                        "criterion": "myositis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "autoimmune hepatitis",
                        "criterion": "autoimmune hepatitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "systemic lupus erythematosus",
                        "criterion": "systemic lupus erythematosus",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "rheumatoid arthritis",
                        "criterion": "rheumatoid arthritis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "inflammatory bowel disease",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "vascular thrombosis associated with antiphospholipid syndrome",
                        "criterion": "vascular thrombosis associated with antiphospholipid syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Wegener's granulomatosis",
                        "criterion": "Wegener's granulomatosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Sjögren's syndrome",
                        "criterion": "Sjögren's syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Guillain-Barré syndrome",
                        "criterion": "Guillain-Barré syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "multiple sclerosis",
                        "criterion": "multiple sclerosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "vasculitis",
                        "criterion": "vasculitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "glomerulonephritis",
                        "criterion": "glomerulonephritis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease. Use of steroids as pre-medication for contrast allergy prior to CT scans is permitted. It is acceptable to use steroids as pre-medication for AMVAC.",
                "criterions": [
                    {
                        "exact_snippets": "Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug.",
                        "criterion": "systemic corticosteroid or immunosuppressive medication use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug.",
                        "criterion": "systemic corticosteroid or immunosuppressive medication use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone or equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug.",
                        "criterion": "systemic corticosteroid or immunosuppressive medication use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug.",
                                "criterion": "systemic corticosteroid or immunosuppressive medication use",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug.",
                                "criterion": "systemic corticosteroid or immunosuppressive medication use",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "mg daily prednisone or equivalent"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug.",
                        "criterion": "systemic corticosteroid or immunosuppressive medication use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrolment.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrolment.",
                        "criterion": "treatment with systemic immunostimulatory agents",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrolment.",
                        "criterion": "treatment with systemic immunostimulatory agents",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study",
                "criterions": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study",
                        "criterion": "allergic reactions to compounds similar to study drugs",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study",
                        "criterion": "allergic reactions to compounds similar to study drugs",
                        "requirement": {
                            "requirement_type": "attribution",
                            "expected_value": "compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study",
                        "criterion": "allergic reactions to compounds similar to study drugs",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study",
                        "criterion": "allergic reactions to compounds similar to study drugs",
                        "requirement": {
                            "requirement_type": "attribution",
                            "expected_value": "compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Doxorubicin or Cisplatin or other agents used in the study"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients who have received experimental agents within 4 weeks of study entry.",
                "criterions": [
                    {
                        "exact_snippets": "received experimental agents within 4 weeks of study entry",
                        "criterion": "receipt of experimental agents",
                        "requirement": {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "received experimental agents within 4 weeks of study entry",
                    "criterion": "receipt of experimental agents",
                    "requirement": {
                        "requirement_type": "time since last receipt",
                        "expected_value": {
                            "operator": ">=",
                            "value": 4,
                            "unit": "weeks"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with CD137 agonists, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with CD137 agonists",
                        "criterion": "prior treatment with CD137 agonists",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-programmed death-1 (PD-1)",
                        "criterion": "prior treatment with anti-programmed death-1 (PD-1) therapeutic antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-PD-L1 therapeutic antibody",
                        "criterion": "prior treatment with anti-PD-L1 therapeutic antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... pathway-targeting agents",
                        "criterion": "prior treatment with pathway-targeting agents",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior treatment with CD137 agonists",
                        "criterion": "prior treatment with CD137 agonists",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-programmed death-1 (PD-1)",
                        "criterion": "prior treatment with anti-programmed death-1 (PD-1) therapeutic antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-PD-L1 therapeutic antibody",
                        "criterion": "prior treatment with anti-PD-L1 therapeutic antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... pathway-targeting agents",
                        "criterion": "prior treatment with pathway-targeting agents",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any component of small cell histology.",
                "criterions": [
                    {
                        "exact_snippets": "Any component of small cell histology.",
                        "criterion": "small cell histology",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any component of small cell histology.",
                        "criterion": "small cell histology",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* ECOG performance status 0, or 1.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status 0, or 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Normal organ and bone marrow function (Leukocytes ≥ 3,000/mcL, Absolute neutrophil count ≥ 1,500/mcL, Platelets ≥ 100,000/mcL, Total bilirubin ≤ institutional upper limit of normal (ULN) unless patient has known Gilbert's disease, in which case an elevated bilirubin is allowed, AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN, Creatinine Clearance ≥ 50 mL/min calculated using the Cockroft-Gault formula or measured with 24 hour urine collection)",
                "criterions": [
                    {
                        "exact_snippets": "Leukocytes ≥ 3,000/mcL",
                        "criterion": "leukocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3000,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1,500/mcL",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets ≥ 100,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ institutional upper limit of normal (ULN) unless patient has known Gilbert's disease, in which case an elevated bilirubin is allowed",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ institutional upper limit of normal (ULN) unless patient has known Gilbert's disease, in which case an elevated bilirubin is allowed",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "elevated bilirubin allowed if patient has known Gilbert's disease"
                        }
                    },
                    {
                        "exact_snippets": "AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN",
                        "criterion": "AST/ALT levels",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine Clearance ≥ 50 mL/min calculated using the Cockroft-Gault formula or measured with 24 hour urine collection",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine Clearance ≥ 50 mL/min calculated using the Cockroft-Gault formula or measured with 24 hour urine collection",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": [
                                "Cockroft-Gault formula",
                                "24 hour urine collection"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Male or female patients ≥18 years",
                "criterions": [
                    {
                        "exact_snippets": "Male or female patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "≥18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 6 months of study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Left ventricular ejection fraction ≥ 50%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular ejection fraction ≥ 50%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "MUGA",
                                "ECHO"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular ejection fraction ≥ 50%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 6 months of study entry"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Primary urothelial or predominantly urothelial carcinoma of the bladder confirmed from pathology report. Patients with some component of variant histology mixed with predominant urothelial carcinoma will be allowed. Upper tract urothelial carcinoma patients are not allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Primary urothelial or predominantly urothelial carcinoma of the bladder confirmed from pathology report",
                        "criterion": "urothelial carcinoma of the bladder",
                        "requirement": {
                            "requirement_type": "histology type",
                            "expected_value": [
                                "primary urothelial carcinoma",
                                "predominantly urothelial carcinoma"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Primary urothelial or predominantly urothelial carcinoma of the bladder confirmed from pathology report",
                        "criterion": "urothelial carcinoma of the bladder",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathology report"
                        }
                    },
                    {
                        "exact_snippets": "Patients with some component of variant histology mixed with predominant urothelial carcinoma will be allowed",
                        "criterion": "variant histology component",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with some component of variant histology mixed with predominant urothelial carcinoma will be allowed",
                        "criterion": "variant histology component",
                        "requirement": {
                            "requirement_type": "mix with predominant urothelial carcinoma",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Upper tract urothelial carcinoma patients are not allowed",
                        "criterion": "upper tract urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* No radiographic evidence of lymph node positive disease as per RECIST 1.1 (≥15 mm short axis diameter). Lymph node positive disease is defined as clinical lymphadenopathy on staging CT or MRI greater than 1.4 cm in the short axis. If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible.",
                "criterions": [
                    {
                        "exact_snippets": "No radiographic evidence of lymph node positive disease as per RECIST 1.1 (≥15 mm short axis diameter)",
                        "criterion": "lymph node positive disease (radiographic evidence)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "No radiographic evidence of lymph node positive disease as per RECIST 1.1 (≥15 mm short axis diameter)",
                        "criterion": "lymph node positive disease (radiographic evidence)",
                        "requirement": {
                            "requirement_type": "measurement (short axis diameter)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Lymph node positive disease is defined as clinical lymphadenopathy on staging CT or MRI greater than 1.4 cm in the short axis",
                        "criterion": "clinical lymphadenopathy on staging CT or MRI",
                        "requirement": {
                            "requirement_type": "measurement (short axis diameter)",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.4,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Lymph node positive disease is defined as clinical lymphadenopathy on staging CT or MRI greater than 1.4 cm in the short axis",
                        "criterion": "clinical lymphadenopathy on staging CT or MRI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible",
                        "criterion": "lymph node biopsy result (if >1.4 cm)",
                        "requirement": {
                            "requirement_type": "measurement (short axis diameter)",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.4,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible",
                        "criterion": "lymph node biopsy result (if >1.4 cm)",
                        "requirement": {
                            "requirement_type": "biopsy result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "No radiographic evidence of lymph node positive disease as per RECIST 1.1 (\u001e15 mm short axis diameter)",
                                "criterion": "lymph node positive disease (radiographic evidence)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "No radiographic evidence of lymph node positive disease as per RECIST 1.1 (\u001e15 mm short axis diameter)",
                                "criterion": "lymph node positive disease (radiographic evidence)",
                                "requirement": {
                                    "requirement_type": "measurement (short axis diameter)",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 15,
                                        "unit": "mm"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "clinical lymphadenopathy on staging CT or MRI greater than 1.4 cm in the short axis",
                                "criterion": "clinical lymphadenopathy on staging CT or MRI",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "clinical lymphadenopathy on staging CT or MRI greater than 1.4 cm in the short axis",
                                "criterion": "clinical lymphadenopathy on staging CT or MRI",
                                "requirement": {
                                    "requirement_type": "measurement (short axis diameter)",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1.4,
                                        "unit": "cm"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible",
                                        "criterion": "lymph node biopsy result (if >1.4 cm)",
                                        "requirement": {
                                            "requirement_type": "measurement (short axis diameter)",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1.4,
                                                "unit": "cm"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible",
                                        "criterion": "lymph node biopsy result (if >1.4 cm)",
                                        "requirement": {
                                            "requirement_type": "measurement (short axis diameter)",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 1.4,
                                                "unit": "cm"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "If a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible",
                                        "criterion": "lymph node biopsy result (if >1.4 cm)",
                                        "requirement": {
                                            "requirement_type": "biopsy result",
                                            "expected_value": "negative"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Patients with hydronephrosis that has not been addressed with a documented assessment (i.e. normal GFR, no intervention necessary) or an intervention such as placement of a stent or nephrostomy tube.",
                "criterions": [
                    {
                        "exact_snippets": "Patients with hydronephrosis that has not been addressed with a documented assessment (i.e. normal GFR, no intervention necessary) or an intervention such as placement of a stent or nephrostomy tube.",
                        "criterion": "hydronephrosis",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "has not been addressed with a documented assessment or an intervention"
                        }
                    },
                    {
                        "exact_snippets": "documented assessment (i.e. normal GFR, no intervention necessary)",
                        "criterion": "hydronephrosis",
                        "requirement": {
                            "requirement_type": "assessment",
                            "expected_value": "documented assessment"
                        }
                    },
                    {
                        "exact_snippets": "documented assessment (i.e. normal GFR, no intervention necessary)",
                        "criterion": "hydronephrosis",
                        "requirement": {
                            "requirement_type": "GFR",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intervention such as placement of a stent or nephrostomy tube",
                        "criterion": "hydronephrosis",
                        "requirement": {
                            "requirement_type": "intervention",
                            "expected_value": [
                                "placement of a stent",
                                "placement of a nephrostomy tube"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Has a known additional malignancy that has had progression or has required active treatments in the last three years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with surgery is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; PSA undetectable for 1 year while off androgen deprivation therapy. Patients on active surveillance for low grade prostate cancer are allowed to participate.",
                "criterions": [
                    {
                        "exact_snippets": "Has a known additional malignancy that has had progression or has required active treatments in the last three years",
                        "criterion": "additional malignancy",
                        "requirement": {
                            "requirement_type": "progression_or_active_treatment_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer",
                        "criterion": "type of additional malignancy",
                        "requirement": {
                            "requirement_type": "exception_types",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin that has undergone potentially curative therapy",
                                "in situ cervical cancer"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "A history of prostate cancer that was treated with surgery is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; PSA undetectable for 1 year while off androgen deprivation therapy",
                        "criterion": "history of prostate cancer treated with surgery",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "T"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "N"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "M"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A history of prostate cancer that was treated with surgery is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; PSA undetectable for 1 year while off androgen deprivation therapy",
                        "criterion": "history of prostate cancer treated with surgery",
                        "requirement": {
                            "requirement_type": "PSA_undetectable_duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A history of prostate cancer that was treated with surgery is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; PSA undetectable for 1 year while off androgen deprivation therapy",
                        "criterion": "history of prostate cancer treated with surgery",
                        "requirement": {
                            "requirement_type": "androgen_deprivation_therapy_status",
                            "expected_value": "off"
                        }
                    },
                    {
                        "exact_snippets": "Patients on active surveillance for low grade prostate cancer are allowed to participate",
                        "criterion": "active surveillance for low grade prostate cancer",
                        "requirement": {
                            "requirement_type": "active_surveillance_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients on active surveillance for low grade prostate cancer are allowed to participate",
                        "criterion": "active surveillance for low grade prostate cancer",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "low"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}